KiSSFLOW Crosses 1000 Signups; Emerges as Top New App on Google Apps Marketplace

Mountain View, CA (PRWEB) October 23, 2012

OrangeScape announced more than 1000 companies from over 80 countries are now using KiSSFLOW. KiSSFLOW is the first workflow creation app specifically built for Google Apps. It offers companies a simple and efficient way to automate workflows around their existing email user base. These companies are now automating their travel claims; leave requests; budget approvals and other HR processes using KiSSFLOW.

“There is an interesting mix of business processes that are getting automated in companies, today” said Mani Doraisamy, Co-Founder and CTO of OrangeScape. “First, they start off by automating simple workflows like leave requests. As their confidence grows, they move on to sophisticated workflows that are domain specific. Healthcare workflow that won our workflow contest last month is good example of such workflow. It also demonstrates how KiSSFLOW can empower process owners to automate their business processes in days, which used to take weeks or even months earlier.”

Last month, KiSSFLOW was added to the Google Apps Marketplace, Google’s online storefront for Google Apps products and services. It became the second most installed workflow app on Google Apps marketplace within the first month of its launch. This month, it reached another milestone to become the top new app across all categories on Google Apps Marketplace.

KiSSFLOW is free for 10 users and 10 workflow processes. The Standard edition is $ 3 per user monthly and $ 18 per workflow creator monthly. Full pricing and availability details can be found online. A free trial is available on the home page.

About OrangeScape

OrangeScape is a leading Platform as a Service (PaaS) company. Its PaaS solution enables the creation of cloud-based, SaaS or on-premise business applications. OrangeScape-based applications have been developed across nearly 100 application categories: time sheet; payroll; loan origination, and more. Customers include AstraZeneca; Citi

Leave a Reply